AU2022409610A1 - Caninized antibodies to canine interleukin-31 receptor alpha 1 - Google Patents

Caninized antibodies to canine interleukin-31 receptor alpha 1 Download PDF

Info

Publication number
AU2022409610A1
AU2022409610A1 AU2022409610A AU2022409610A AU2022409610A1 AU 2022409610 A1 AU2022409610 A1 AU 2022409610A1 AU 2022409610 A AU2022409610 A AU 2022409610A AU 2022409610 A AU2022409610 A AU 2022409610A AU 2022409610 A1 AU2022409610 A1 AU 2022409610A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
ser
acid sequence
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022409610A
Other languages
English (en)
Inventor
Mohamad Morsey
Yuanzheng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of AU2022409610A1 publication Critical patent/AU2022409610A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022409610A 2021-12-16 2022-12-15 Caninized antibodies to canine interleukin-31 receptor alpha 1 Pending AU2022409610A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163290256P 2021-12-16 2021-12-16
US202163290259P 2021-12-16 2021-12-16
US63/290,259 2021-12-16
US63/290,256 2021-12-16
US202263341443P 2022-05-13 2022-05-13
US63/341,443 2022-05-13
PCT/EP2022/086084 WO2023111148A1 (en) 2021-12-16 2022-12-15 Caninized antibodies to canine interleukin-31 receptor alpha 1

Publications (1)

Publication Number Publication Date
AU2022409610A1 true AU2022409610A1 (en) 2024-05-30

Family

ID=84923386

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022409610A Pending AU2022409610A1 (en) 2021-12-16 2022-12-15 Caninized antibodies to canine interleukin-31 receptor alpha 1
AU2022409603A Pending AU2022409603A1 (en) 2021-12-16 2022-12-15 Caninized antibodies to canine interleukin-31 receptor alpha ii

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022409603A Pending AU2022409603A1 (en) 2021-12-16 2022-12-15 Caninized antibodies to canine interleukin-31 receptor alpha ii

Country Status (7)

Country Link
US (2) US20250340653A1 (https=)
EP (2) EP4448571A1 (https=)
JP (2) JP2024546759A (https=)
AU (2) AU2022409610A1 (https=)
CA (2) CA3239826A1 (https=)
MX (2) MX2024007090A (https=)
WO (2) WO2023111148A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116744917A (zh) 2020-09-04 2023-09-12 礼蓝美国公司 适口调配物
WO2025174998A1 (en) * 2024-02-13 2025-08-21 Invetx, Inc. Anti-il-31ra antibodies and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
ES2443022T3 (es) 2005-08-12 2014-02-17 Merck Frosst Canada Inc. Derivados de indol como antagonistas del receptor CRTH2
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
AU2009295229B2 (en) 2008-09-22 2014-02-27 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
AU2009295231A1 (en) 2008-09-22 2010-03-25 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
WO2011075517A1 (en) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP6701079B2 (ja) 2013-12-20 2020-05-27 インターベット インターナショナル ベー． フェー． ヒトｐｄ−１に対するイヌ化マウス抗体
WO2018073185A1 (en) * 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
AU2017376398B2 (en) 2016-12-14 2021-07-15 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
US11542333B2 (en) * 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
MX2022007636A (es) * 2019-12-20 2022-07-19 Intervet Int Bv Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.

Also Published As

Publication number Publication date
US20250340654A1 (en) 2025-11-06
MX2024007090A (es) 2024-08-22
EP4448572A1 (en) 2024-10-23
CA3239307A1 (en) 2023-06-22
JP2024546763A (ja) 2024-12-26
MX2024007089A (es) 2024-08-22
WO2023111148A1 (en) 2023-06-22
EP4448571A1 (en) 2024-10-23
AU2022409603A1 (en) 2024-06-27
US20250340653A1 (en) 2025-11-06
CA3239826A1 (en) 2023-06-22
WO2023111128A1 (en) 2023-06-22
JP2024546759A (ja) 2024-12-26

Similar Documents

Publication Publication Date Title
US20250277034A1 (en) Caninized Antibodies
US20250179199A1 (en) Antibodies to canine interleukin-4 receptor alpha
US12577310B2 (en) Caninized antibodies to canine interleukin-31 receptor alpha
US20230053131A1 (en) Antibodies to canine interleukin-4 receptor alpha
US20250340654A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha ii
US20250340626A1 (en) Caninized antibodies to human ngf
RU2855920C1 (ru) Канинизированные антитела против альфа-рецептора интерлейкина-31 собаки
HK40113191A (zh) 犬白介素-31受体αI的犬源化抗体
CN118891282A (zh) 犬白介素-31受体αII的犬源化抗体
HK40126994A (en) Caninized antibodies

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MORSEY, MOHAMAD AND ZHANG, YUANZHENG